You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The Yale professor said that deep-learning algorithms could give digital pathology the push it needs for broader adoption.
The firm said that with its mimetope peptide assays, which measure the concentration of blood in a sample, patients would receive the right dose of the right drug.
The polygenic score snags a greater percentage of people at risk of early heart attack than current tests that rely on single-gene variants or blood chemistry.
The device consists of a reservoir that enables the analyte to contact only the top of a screen-printed electrode, increasing sensitivity.
Its CEO said that although a hospital screening test for sepsis is a focus, a fever test that informs about antibiotic use could be available sooner.
Quest will have a broader relationship with Cleveland Clinic in diagnostic development, the companies say.
One firm, Exosome Diagnostics, is working to streamline payor coverage for a commercial test, and researchers are simultaneously developing promising ways to isolate exosomes.
Having demonstrated their ATR-FTIR technique in mice, the researchers are moving to human samples and they plan to be in clinical trials in around two years.
The researchers said that their nanoparticle technology, which detects infrared light, could eventually guide more precise breast cancer surgeries.
The firm's CEO said that the test must undergo additional clinical studies, but it could be available from a CLIA-certified lab in about a year and a half.